Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior Therapy

Key facts

Sponsor

Yujun DONG

Intervention

Gecacitinib Hydrochloride Tablets(drug)

Enrollment

24 enrolled

Eligibility

18 years · All sexes

Timeline

2025 – 2029

Study locations (1)

• Peking University First Hospital, Beijing, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Chronic graft versus host disease

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07394608
  Paired Non-invasive VNS in Adolescent Cerebral Palsy Rehabilitation
  Icahn School of Medicine at Mount Sinai
• RECRUITINGPHASE2NCT07124078
  A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
  Incyte Corporation
• RECRUITINGEARLY PHASE1NCT07355868
  Treatment of Chronic Obstructive Pulmonary Disease (COPD) by REGEND007 Cell Therapy
  Regend Therapeutics
• RECRUITINGNANCT06857929
  "Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition"
  IMDEA Food
• RECRUITINGPHASE1NCT07389044
  A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B
  IntegerBio
• RECRUITINGNCT07127926
  Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD
  M.D. Anderson Cancer Center
• RECRUITINGPHASE1NCT07138196
  A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease
  Qurient Co., Ltd.
• ACTIVE NOT RECRUITINGNCT07321080
  Central Sensitisation in Nociceptive and Neuropathic Pain
  IRCCS Centro Neurolesi Bonino Pulejo

See all trials for Chronic graft versus host disease →